PCI Biotech: First quarter 2016 report

Oslo, 3 May 2016

Please find attached the first quarter 2016 report for PCI Biotech Holding ASA.

Highlights include:

  • Completed dose escalation in the bile duct cancer study, with promising early signs of efficacy
  • Initiated our first research collaboration in the field of cancer vaccination
  • Progressing the vaccination technology towards clinical validation
  • Launching three well-defined strategic development areas: fima CHEM , fima VACC and fima NAc

CEO Per Walday comments:    
"We were pleased to announce completion of dose escalation in the fimaporfin (Amphinex®) Phase I/II bile duct cancer study, with good safety and promising early signs of efficacy. We are confident that Amphinex has potential to provide clinical benefit in this orphan disease with a high need of new local treatment options. We have expanded the last dose cohort to gain further clinical data in anticipation of Phase II start.

The first research agreement in the field of cancer vaccination was also an important milestone for the company. Our preclinical research combining the PCI technology with peptide vaccines have demonstrated strong enhancement of important cellular immune responses. The research has already been initiated and we look forward to exploring synergistic effects in this collaboration with Ultimovacs.

The strategic refocusing has resulted in three clearly defined development areas for fimaporfin (Amphinex), with the advantage of shared technological solutions in multiple business opportunities with different risk profiles."

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.

The company has a clinical Phase I/II program in bile duct cancer, which is an orphan indication without approved medicinal products and a high need for better local treatments. The indication is well suited for PCI treatment, with easy light access through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI. 

The company is also developing PCI as a vaccination technology. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

The PCI technology is also very well suited for intracellular delivery of nucleic acids, such as RNA therapeutics. By releasing nucleic acid compounds from endosomes where they are trapped following administration, PCI addresses one of the major bottlenecks facing this emerging and exciting field.

For more information visit: www.pcibiotech.com

Contact information:  
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo    
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

PCI Biotech 1Q 2016 Report

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PCI Biotech Holding via GlobeNewswire